Healx

We’re partnering with SCI Ventures to use AI to uncover treatments for paralysis. Together, we aim to accelerate therapies for spinal cord injury and beyond. 🚀 Learn more: healx.ai/healx-and-sci-ventu…

Big news! 🚀 Healx welcomes Dr. Chris Moertel as our Global Head of Clinical Development. His expertise in #Neurofibromatosis and rare disease clinical research will accelerate our mission. Welcome, Chris! 🎉 #RareDisease #DrugDiscovery #ClinicalDevelopment

From shared vision to changing lives. In 2013, our co-founders Dr. David Brown & Tim Guilliams met for the first time — a conversation that sparked the creation of Healx and a new approach to discovering and developing treatments for rare diseases. Now, we’ve just dosed the first patient in our Phase 2 trial for HLX-1502, our investigational therapy for #NF1. Watch Dr. Brown share the story & our progress. #RareDisease #NF1 #Biotech #DrugDiscovery

🚀 Big milestone! The first patient has been dosed in INSPIRE-NF1, our Phase 2 study of HLX-1502 for #NF1, a rare genetic disorder affecting ~1 in 2,500 people. This is a huge step forward in our mission to use #AI & tech to drive breakthroughs for #raredisease patients. Hear from our co-founder & CEO Tim Guilliams on why this matters. 🔗 healx.ai/healx-announces-fir… #NF1Awareness #Biotech #Innovation #AIforGood #RareDiseases

In honor of International Day of Women and Girls in Science, we’re celebrating the incredible women at Healx who are helping to pave the way in AI-driven drug discovery for #rarediseases. We believe in fostering a more inclusive future where women and girls are empowered to shape the next breakthroughs in science and technology, we’re proud to support a workplace where diverse perspectives drive progress and impact. #IDWGS #WomenInScience

Our CEO @TimGuillams sat down with the @GlobalGenes RARECast podcast team to discuss the unique ways Healx is harnessing #AI to develop treatments for #rarediseases, starting with neurofibromatosis type 1 (#NF1). Listen now for more on Healx’s origins, our progress to date, and Tim’s take on AI’s impact on drug discovery. globalgenes.org/raredaily/us…

Excited for #JPM25 next week in San Francisco! Our CEO, Tim Guilliams, will be there—say hello if you see him! Let’s connect to share insights and collaborate on transforming lives for #raredisease patients through generative #AI. #AIForGood #HealthcareInnovation @jpmorganhealth

Another quarterly team days meeting in the books! We enjoyed coming together in Cambridge one final time before the end of the year to reflect on the progress made in 2024 and the strides we have made in leveraging the power of generative AI to bring new treatments to patients. Our advancements wouldn’t be possible without the dedication and passion of this talented team and the partnerships we’ve fostered with organisations and collaborators around the world. And to top it all off, even Father Christmas stopped by to celebrate the season and the team’s hard work!

Our co-founder and CEO Tim Guilliams is looking forward to participating in a panel discussion on how #AI is reshaping healthcare at @Balderton’s “From code to cure: AI's reshaping of drug discovery” event in London. Tim will highlight how Healx is leveraging generative AI to build a pipeline of patient-inspired treatments for #rarediseases

We are pleased to announce the appointment of Jonathan Milner, Ph.D., as the new non-executive chairman of the board, effective immediately. Dr. Milner is a distinguished entrepreneur and an influential figure in the UK life sciences and #biotech industry with a strong track record of fostering innovation. In addition to serving on several boards, he has contributed his expertise to numerous startups and established organisations, and we are grateful to have him at Healx. This transition comes as current chairman and co-founder David Brown, Ph.D., begins a secondment to pursue academic research at Trinity College, Cambridge University. Dr. Brown will remain an active member of the Healx board, continuing to contribute and support Tim Guilliams, Ph.D., co-founder and CEO of Healx, and Dr. Milner in advancing Healx’s mission. Read more about this update here: healx.ai/jonathan-milner-ph-…

We're extending our sincerest congratulations to Healx Co-founder David Brown, Ph.D., for being awarded the 2024 @OBN_UK Awards Special Recognition Award. Over the span of 50 years, and in addition to his leadership at Healx, he has worked with leading pharmaceutical companies and is responsible for many tremendous achievements, including the co-invention of Viagra during his time at Pfizer. His many accomplishments include improving access to medicines in less advantaged countries, sponsoring a global challenge to find innovative treatments for sepsis, and becoming an entrepreneur coach at Cambridge University Business School. We're grateful to work closely with Dr. Brown as he helps guide our mission of creating generative AI-powered, patient-inspired treatments for people living with #rarediseases.

We are proud to partner with the @ChildrensTumor Foundation (CTF) since 2020 to combine our cutting-edge #AI platform and drug discovery expertise with CTF’s preclinical and clinical research and patient knowledge in identifying novel treatments for #rarediseases including Neurofibromatosis Type 1 (#NF1). In the video below, hear from our Head of Neurofibromatosis Therapy Development and CEO/President of CTF as they discuss the importance of patient-centric research and how the partnership is beneficial in gaining patients' perspectives.

Important collaboration update: we just announced that we will be analyzing data from a proprietary Sanofi compound using Healnet, our #AI-driven #drugdiscovery platform, in order to identify new disease indications for this asset. Read More: healx.ai/healx-announces-agr…

Our Senior Director, Drug Discovery and Head of Operations, People & Tech will be participating in the @OBN_UK BioTuesday session next week in London. They will contribute to a conversation about the funding landscape and regulatory challenges within the #raredisease space and hear first-hand from a rare disease patient group. Read more about the event here: obn.glueup.com/event/112314/

Growth is a journey fuelled by curiosity, collaboration, and mutual respect for one another. Our team is dedicated to learning, sharing knowledge, and amplifying every voice to drive meaningful impact for the #raredisease community. By embracing diverse perspectives and fostering an environment of trust, we empower one another to continuously evolve and excel, leading to better outcomes. Learn more about our company values here: healx.ai/about/

Exciting Progress in Rare Disease Treatment at Healx! Proud to share that our lead program, HLX-1502, has received FastTrack designation from the FDA, bringing us one step closer to delivering a breakthrough treatment for neurofibromatosis type 1 (NF1). This designation underscores the urgent need for new therapeutic options in NF1 and accelerates our path to making a real impact for patients and their families. Explore our latest blog to learn more about HLX-1502, what FastTrack means for our team and the NF1 community, and the next steps in our journey. Read more on our website: healx.ai/u-s-fda-grants-fast… #Healx #RareDisease #NF1 #FastTrack #Biotech #FDA